학술논문

Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage.
Document Type
article
Source
Journal of Alzheimer's Disease. 78(1)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Acquired Cognitive Impairment
Brain Disorders
Dementia
Neurodegenerative
Alzheimer's Disease
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Neurosciences
Aging
Neurological
Aged
Aged
80 and over
Alzheimer Disease
Amyloid beta-Peptides
Amyloidogenic Proteins
Amyloidosis
Aniline Compounds
Brain
Cognitive Dysfunction
Cohort Studies
Cross-Sectional Studies
Ethylene Glycols
Female
Glial Fibrillary Acidic Protein
Humans
Male
Positron-Emission Tomography
Radiopharmaceuticals
Thiazoles
tau Proteins
Alzheimer's disease
amyloid
astrocyte
biomarker
glial fibrillary acidic protein
plasma
Alzheimer’s disease
Cognitive Sciences
Neurology & Neurosurgery
Clinical sciences
Biological psychology
Language
Abstract
BackgroundMeasuring plasma glial fibrillary acidic protein (GFAP) alongside cortical amyloid-β (Aβ) may shed light on astrocytic changes in aging and Alzheimer's disease (AD).ObjectiveTo examine associations between plasma GFAP and cortical Aβ deposition in older adults across the typical aging-to-AD dementia spectrum.MethodsWe studied two independent samples from UCSF (Cohort 1, N = 50; Cohort 2, N = 37) covering the spectra of clinical severity (CDR Sum of Boxes; CDR-SB) and Aβ-PET burden. Aβ-PET was completed with either florbetapir or Pittsburgh Compound B and standardized uptake value ratios were converted to the Centiloid (CL) scale for analyses. All participants with CDR-SB > 0 were Aβ-PET positive, while clinically normal participants (CDR-SB = 0) were a mix of Aβ-PET positive and negative. Regression analyses evaluated main effect and interaction associations between plasma GFAP, Aβ-PET, and clinical severity.ResultsIn both cohorts, plasma GFAP increased linearly with Aβ-PET CLs in clinically normal older adults. In Cohort 2, which included participants with more severe clinical dysfunction and Aβ-PET burden, the association between Aβ and GFAP became curvilinear (inverted U-shape; quadratic model R2 change = 0.165, p = 0.009), and Aβ-PET interacted with CDR-SB (R2 change = 0.164, p = 0.007): older adults with intermediate functional impairment (CDR-SB = 0.5-4.0) showed a weak (negative) association between Aβ-PET CLs and plasma GFAP, while older adults with dementia (CDR-SB > 4.0) showed a strong, negative association of higher Aβ-PET CLs with lower plasma GFAP.ConclusionThe relationship between astrocytic integrity and cortical Aβ may be highly dynamic, with linear, positive associations early in disease that diverge in more severe disease stages.